TextRanch

The best way to perfect your writing.

Discover why 1,062,726 users count on TextRanch to get their English corrected!

1. Input your text below.
2. Get it corrected in a few minutes by our editors.
3. Improve your English!

One of our experts will correct your English.

Our experts

in patients that vs in patients who

Both 'in patients that' and 'in patients who' are commonly used in English, but 'in patients who' is more widely accepted and preferred. 'Who' is generally used to refer to people, while 'that' can be used for both people and things, but it is less common when referring to people.

Last updated: March 26, 2024

in patients that

This phrase is correct but less common than 'in patients who'. 'That' can be used to refer to people, but 'who' is more widely accepted in this context.

This phrase can be used to refer to patients, but 'who' is generally preferred when referring to people.
  • A survival benefit was also demonstrated in patients that had not achieved a complete/ partial response following azacitidine treatment.
  • Caution should be exercised in patients that have previously shown hypersensitivity reactions to cefovecin, other cephalosporins, penicillins, or other drugs.
  • - It happens in patients that have m...
  • I want a guy that can direct me towards a better scientific understanding of just why a fistula may occur in patients that are healthy one minute and die the next.
  • Response rate (investigator assessment) in patients that crossed over to panitumumab after progression on BSC alone was 22% (95% CI:
  • There are currently no data regarding the reuse of CELSENTRI in patients that currently have only CCR5-tropic HIV-1 detectable, but have a history of failure on CELSENTRI (or other CCR5 antagonists) with a CXCR4 or dual/ mixed tropic virus.
  • The same results were confirmed in patients that were unsuitable for other systemic therapies (see Table 1 below).
  • Other severe events occurring in patients that were recorded as related or possibly related to topotecan treatment were anorexia (12%), malaise (3%) and hyperbilirubinaemia (1%).
  • Dosage adjustment is necessary in patients with severe renal impairment and in patients that require haemodialysis (see section 4.2).

Alternatives:

  • in patients who

in patients who

This phrase is correct and widely accepted. 'Who' is generally used to refer to people, and it is the preferred choice in this context.

This phrase is commonly used to refer to patients or individuals in a medical or healthcare context.
  • Kivexa, Trizivir), MUST NEVER be restarted in patients who have stopped therapy due to a hypersensitivity reaction.
  • The doctor may interrupt treatment in patients who develop a serious infection.
  • Consideration must be given to discontinuing Zonegran in patients who develop an otherwise unexplained rash.
  • Zalasta is also effective in maintaining improvement in patients who have responded to an initial course of treatment.
  • MIRCERA should be used with caution in patients who have severe problems with their liver.
  • It must not be used in patients who have liver problems.
  • It must not be used in patients who have an active infection that the doctor considers important.
  • Slipped capital femoral epiphysis and progression of scoliosis can occur in patients who experience rapid growth.
  • Slipped capital femoral epiphysis and progression of scoliosis can occur in patients who experience rapid growth.
  • The safety of continuation or resumption of Herceptin in patients who experience cardiotoxicity has not been prospectively studied.
  • RELISTOR should only be used in patients who are receiving palliative care.
  • Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic benefit after dose adjustment.
  • Renagel treatment should be re- evaluated in patients who develop severe constipation or other severe gastrointestinal symptoms.
  • A slower injection is preferable in patients who react to the treatment with "flu-like" symptoms.
  • Combination therapy with alpha interferons should be discontinued in patients who develop new or worsening ophthalmologic disorders.
  • Discontinue treatment in patients who develop prolongation of coagulation markers which might indicate liver decompensation.
  • Discontinue treatment in patients who develop prolongation of coagulation markers which might indicate liver decompensation.
  • Doses may need to be lower in patients who have certain side effects.
  • Therapy should only be continued in patients who have responded to treatment.
  • ge treatment in patients who develop malignancy while receiving Trudexa.

Alternatives:

  • in patients that

Related Comparisons

in that vs Taken togther patients that vs patients who in that vs in that that given that vs in that for that vs in that will cost about vs in that

What Our Customers Are Saying

Our customers love us! We have an average rating of 4.79 stars based on 283,125 votes.
Also check out our 2,100+ reviews on TrustPilot (4.9TextRanch on TrustPilot).

Why choose TextRanch?

Lowest prices
Up to 50% lower than other online editing sites.

Fastest Times
Our team of editors is working for you 24/7.

Qualified Editors
Native English experts for UK or US English.

Top Customer Service
We are here to help. Satisfaction guaranteed!